Keywords: exelixis, receive, up, 157m, wyeth, fxr, deal

Exelixis to receive up to $157M in Wyeth FXR deal

Article | 09 January 2006

Print This

US biotechnology firm Exelixis has signed a license agreement with drug major Wyeth related to compounds targeting the farnesoid X ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in